End-of-day quote
Korea S.E.
18:00:00 2024-05-02 EDT
|
5-day change
|
1st Jan Change
|
771,000
KRW
|
-0.52%
|
|
+0.13%
|
+1.45%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
54,652,290
|
59,746,995
|
58,433,854
|
54,092,240
|
54,875,154
|
-
|
-
|
Enterprise Value (EV)
2 |
55,086
|
59,668
|
57,746
|
53,840
|
53,133
|
52,126
|
51,125
|
P/E ratio
|
-
|
152
x
|
71.8
x
|
63.1
x
|
56.3
x
|
47.9
x
|
40
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
46.9
x
|
38.1
x
|
19.5
x
|
14.6
x
|
12.9
x
|
11.2
x
|
9.8
x
|
EV / Revenue
|
47.3
x
|
38.1
x
|
19.2
x
|
14.6
x
|
12.5
x
|
10.6
x
|
9.13
x
|
EV / EBITDA
|
126
x
|
85.4
x
|
44.7
x
|
33.6
x
|
29.3
x
|
25.5
x
|
21.6
x
|
EV / FCF
|
882
x
|
1,234
x
|
-15,229
x
|
80.2
x
|
54.5
x
|
54.2
x
|
49.7
x
|
FCF Yield
|
0.11%
|
0.08%
|
-0.01%
|
1.25%
|
1.84%
|
1.85%
|
2.01%
|
Price to Book
|
11.9
x
|
12
x
|
6.38
x
|
5.5
x
|
5.08
x
|
4.6
x
|
4.14
x
|
Nbr of stocks (in thousands)
|
66,165
|
66,165
|
71,174
|
71,174
|
71,174
|
-
|
-
|
Reference price
3 |
826,000
|
903,000
|
821,000
|
760,000
|
771,000
|
771,000
|
771,000
|
Announcement Date
|
21-01-26
|
22-01-24
|
23-01-27
|
24-01-24
|
-
|
-
|
-
|
1KRW in Million2KRW in Billions3KRW Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,165
|
1,568
|
3,001
|
3,695
|
4,264
|
4,921
|
5,598
|
EBITDA
1 |
436.5
|
699.1
|
1,292
|
1,603
|
1,815
|
2,042
|
2,363
|
EBIT
1 |
292.8
|
537.3
|
983.6
|
1,114
|
1,256
|
1,503
|
1,769
|
Operating Margin
|
25.14%
|
34.27%
|
32.77%
|
30.14%
|
29.47%
|
30.54%
|
31.6%
|
Earnings before Tax (EBT)
1 |
-
|
561.3
|
1,009
|
1,120
|
1,250
|
1,495
|
1,798
|
Net income
1 |
-
|
393.6
|
798.1
|
857.7
|
974.5
|
1,176
|
1,373
|
Net margin
|
-
|
25.1%
|
26.59%
|
23.21%
|
22.85%
|
23.9%
|
24.53%
|
EPS
2 |
-
|
5,949
|
11,432
|
12,051
|
13,691
|
16,089
|
19,293
|
Free Cash Flow
3 |
62,425
|
48,343
|
-3,792
|
671,158
|
975,340
|
961,780
|
1,029,270
|
FCF margin
|
5,359.41%
|
3,083.07%
|
-126.34%
|
18,165.97%
|
22,873.68%
|
19,544.32%
|
18,385.26%
|
FCF Conversion (EBITDA)
|
14,302.14%
|
6,915.01%
|
-
|
41,856.8%
|
53,724.58%
|
47,101.96%
|
43,561.3%
|
FCF Conversion (Net income)
|
-
|
12,282.53%
|
-
|
78,251.71%
|
100,086.2%
|
81,791.34%
|
74,962.48%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-01-26
|
22-01-24
|
23-01-27
|
24-01-24
|
-
|
-
|
-
|
1KRW in Billions2KRW3KRW in Million Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
450.7
|
444.3
|
511.3
|
651.4
|
873
|
965.5
|
720.9
|
866.2
|
1,034
|
1,074
|
946.9
|
986.5
|
1,060
|
1,240
|
1,212
|
EBITDA
1 |
208.2
|
171
|
215.9
|
258.6
|
409.4
|
405.2
|
292.4
|
362.1
|
457.9
|
-
|
353
|
457.2
|
496.5
|
547.9
|
-
|
EBIT
1 |
167.4
|
128.8
|
176.4
|
169.7
|
324.7
|
312.8
|
191.7
|
253.4
|
318.5
|
350
|
221.3
|
301.5
|
317.6
|
395.7
|
410.9
|
Operating Margin
|
37.14%
|
29%
|
34.5%
|
26.05%
|
37.2%
|
32.4%
|
26.6%
|
29.26%
|
30.81%
|
32.6%
|
23.37%
|
30.56%
|
29.96%
|
31.91%
|
33.9%
|
Earnings before Tax (EBT)
1 |
-
|
109.2
|
198.5
|
214.5
|
198.4
|
397.6
|
196.6
|
251.3
|
316.3
|
355.7
|
240.1
|
333.9
|
299.5
|
398.8
|
407.9
|
Net income
1 |
131.8
|
79.32
|
146.9
|
152
|
129.2
|
369.9
|
141.8
|
184.9
|
240.4
|
290.7
|
179.4
|
236.7
|
233
|
321.6
|
310
|
Net margin
|
29.24%
|
17.85%
|
28.74%
|
23.34%
|
14.79%
|
38.31%
|
19.66%
|
21.34%
|
23.25%
|
27.08%
|
18.94%
|
23.99%
|
21.98%
|
25.93%
|
25.58%
|
EPS
2 |
-
|
-
|
-
|
-
|
1,815
|
5,258
|
1,992
|
2,597
|
3,376
|
4,084
|
2,749
|
3,105
|
3,315
|
4,178
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-10-26
|
22-01-24
|
22-04-27
|
22-07-27
|
22-10-26
|
23-01-27
|
23-04-24
|
23-07-26
|
23-10-25
|
24-01-24
|
24-04-24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
434
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
78.7
|
688
|
253
|
1,742
|
2,750
|
3,750
|
Leverage (Debt/EBITDA)
|
0.9932
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
2 |
62,425
|
48,343
|
-3,792
|
671,158
|
975,340
|
961,780
|
1,029,270
|
ROE (net income / shareholders' equity)
|
5.38%
|
8.21%
|
11.4%
|
9.12%
|
9.64%
|
10.3%
|
11.1%
|
ROA (Net income/ Total Assets)
|
3.91%
|
5.47%
|
6.5%
|
5.26%
|
5.82%
|
6.46%
|
7.18%
|
Assets
1 |
-
|
7,197
|
12,277
|
16,314
|
16,734
|
18,190
|
19,116
|
Book Value Per Share
3 |
69,505
|
75,434
|
128,700
|
138,119
|
151,841
|
167,439
|
186,457
|
Cash Flow per Share
3 |
-
|
11,233
|
13,652
|
23,411
|
21,419
|
23,299
|
27,328
|
Capex
1 |
140
|
406
|
957
|
995
|
1,077
|
940
|
793
|
Capex / Sales
|
11.99%
|
25.91%
|
31.88%
|
26.93%
|
25.26%
|
19.1%
|
14.17%
|
Announcement Date
|
21-01-26
|
22-01-24
|
23-01-27
|
24-01-24
|
-
|
-
|
-
|
1KRW in Billions2KRW in Million3KRW Last Close Price
771,000
KRW Average target price
1,034,261
KRW Spread / Average Target +34.15% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.45% | 40.51B | | -3.79% | 88.14B | | -15.94% | 31.67B | | +52.66% | 24.62B | | -14.50% | 15.65B | | -9.12% | 11.97B | | -14.38% | 12.07B | | -42.56% | 11.61B | | +4.87% | 8.81B | | -4.33% | 8.5B |
Biopharmaceuticals
|